Moderna $MRNA Surges 150% After Phase 3 Cancer Win

Moderna shares exploded as much as 150% on Wednesday after the company and Merck said their personalized mRNA cancer vaccine succeeded in a late-stage melanoma trial. The move came on the back of a William Blair upgrade and marked Moderna’s best trading day ever, as investors rushed to reprice the company’s oncology pipeline.

What Happened

The catalyst was positive Phase 3 data for intismeran autogene, Moderna and Merck’s personalized mRNA vaccine, in patients with high-risk melanoma. The combination with Keytruda met the trial’s main goal of extending the time before cancer returned, while also reducing the risk of distant spread compared with Keytruda alone.

Trading was ferocious. More than 74 million shares changed hands before the first hour was out, far above Moderna’s roughly 5.8 million share 10-day average for a full session. The stock’s surge eclipsed its prior record one-day gain, which had been set in early 2020 when the market began pricing in Moderna’s COVID vaccine potential.

The result matters because it is the first clear late-stage validation of an mRNA-based cancer vaccine platform in melanoma. That opens a much larger potential market than COVID and gives the broader sector a fresh proof point for personalized medicine.

Analyst Take

William Blair upgraded Moderna after the readout, adding institutional support to the move and reinforcing the market’s view that the trial could be a platform-defining event. The upgrade helped extend the rally as investors shifted from speculation to a more concrete commercial narrative.

For bulls, the takeaway is straightforward: the trial win reduces the “COVID-only” discount on Moderna and raises the probability that its mRNA engine can work in oncology. For skeptics, the setup still depends on execution, regulatory follow-through, and whether the data translate into a durable treatment franchise.

What to Watch

Whether Moderna and Merck provide deeper efficacy and safety details from the melanoma study.
How the market reacts in the next few sessions after the initial momentum trade cools.
Whether the readthrough lifts other mRNA names and the broader biotech group again.
Any guidance on regulatory filing plans and next steps for intismeran autogene.
Whether investors begin valuing Moderna more as an oncology platform and less as a post-pandemic vaccine company.

Moderna $MRNA Surges 150% After Phase 3 Cancer Win